Form 4: Immix Biopharma Director Jason Hsu Reports Recent Stock Purchases

Director Jason Hsu of Immix Biopharma, Inc. reports purchasing shares of common stock in two transactions this month.

Summary

• Jason Hsu, a director at Immix Biopharma, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On July 18, 2024, Hsu purchased 3,200 shares of common stock at a weighted average price of $2.0748 per share.
• On July 24, 2024, Hsu purchased 6,000 shares of common stock at a weighted average price of $2.1462 per share.
• Following these transactions, Hsu directly owns 822,200 shares of Immix Biopharma common stock.
• Hsu also indirectly owns 3,915,913 shares through VERITAS LIBERABIT VOS, LLC and 50,000 shares through Signature Collection Properties, LLC.
• Hsu disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of stock purchases by a director. The purchases themselves could be seen as slightly positive, but the document is primarily informational.

Positives

• The director's purchase of shares could be interpreted as a positive signal about the company's prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders.

Stakeholder Impact

• Shareholders may view the director's stock purchases as a positive sign.

Key Dates